Recruiting

Phase 2

CLAG-MTrial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Sponsor:

New York Medical College

Code:

NCT01513603

Conditions

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Burkitts Leukemia/Lymphoma

Chronic Myelogenous Leukemia

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

CLAG-M

Study Details

Brief summary:

CLAG-M is an active, well tolerated regimen in acute myelogenous leukemia. Each of the agents is active in Acute Lymphoblastic Leukemia (ALL) as well. The current trial will determine the efficacy of the regimen in patients with relapsed ALL.

Conditions

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Burkitts Leukemia/Lymphoma

Chronic Myelogenous Leukemia

Study ID

NCT01513603

Start date

Jan, 2012

Status verified date

Jan, 2012

Completion date

Jan, 2014

Anticipated

Primary completion date

Jan, 2014

Anticipated

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Relapsed or refractory acute lymphoblastic leukemia,
Burkitts leukemia/lymphoma,
Lymphoid blastic CML,
Lymphoblastic lymphoma.

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: CLAG-M

Interventions

CLAG-M

IV times 5 days

CLAG-M

Chemotherapy

Primary outcome measure

Complete remission percentage [ Time Frame: 1 month ]

Central Contacts and Locations

Central contacts

Karen Seiter, MD

914 493 7514 karen_seiter@nymc.edu

Nasir Ahmed, MD

914 493 7514 nasir_ahmed@nymc.edu

Locations

Westchester Medical Center/New York Medical College

Recruiting

Valhalla, New York, United States, 10595

Contacts

Karen Seiter, MD

914-493-7514 karen_seiter@nymc.edu

Principal Investigator:

Karen Seiter, MD

More Information

Sponsor

New York Medical College

Last update posted

Jan 20, 2012

Last verified

Jan, 2012

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by New York Medical College on 2012-01-20.